To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
92 Newest Publications about the topic active pharmaceutical ingredients
rss
Passivation of high‐surface‐energy sites of milled ibuprofen crystals via dry coating for reduced cohesion and improved flowability
09-05-2013 | Xi Han, Laila Jallo, Daniel To, Chinmay Ghoroi, Rajesh Davé, Journal of Pharmaceutical Sciences, 2013
Abstract Ibuprofen micronization with dry coating is investigated to examine its influence on passivation/stabilization of high‐surface‐energy sites and reduced cohesion. A fluid energy mill was used to micronize ibuprofen particles down to 5–28 μm with or without simultaneous nanosilica ...
The challenge of improved secretory production of active pharmaceutical ingredients in Saccharomyces cerevisiae: A case study on human insulin analogues
16-04-2013 | Ali Kazemi Seresht, Eva A. Palmqvist, Gerd Schluckebier, Ingrid Pettersson, Lisbeth Olsson, Biotechnology and Bioengineering, 2013
Abstract The yeast Saccharomyces cerevisiae has widely been used as a host for the production of heterologous proteins. Great attention has been put on improved secretory production of active pharmaceutical ingredients, and the secretory pathway of this eukaryotic host has been the ...
Structural characterization of pharmaceutical heparins prepared from different animal tissues
21-03-2013 | Li Fu, Guoyun Li, Bo Yang, Akihiro Onishi, Lingyun Li, Peilong Sun, Fuming Zhang, Robert J. Linhardt, Journal of Pharmaceutical Sciences, 2013
Abstract Although most pharmaceutical heparin used today is obtained from porcine intestine, heparin has historically been prepared from bovine lung and ovine intestine. There is some regulatory concern about establishing the species origin of heparin. This concern began with the outbreak ...
Measurement of active content in escitalopram tablets by a near‐infrared transmission spectroscopy model that encompasses batch variability
05-02-2013 | Solveig Warnecke, Åsmund Rinnan, Morten Allesø, Søren Balling Engelsen, Journal of Pharmaceutical Sciences, 2013
Abstract Near‐infrared transmission (NIT) spectroscopy, with high‐performance liquid chromatography as reference method, was used to study the variation of the active pharmaceutical ingredient (API), escitalopram, in five tablet batches (4%–12%, w/w) manufactured by direct compression. ...
Formation of Stable Nanocarriers by in Situ Ion Pairing during Block-Copolymer-Directed Rapid Precipitation
24-12-2012 | Nathalie M. Pinkerton; Arnaud Grandeury; Andreas Fisch; Jörg Brozio; Bernd U. Riebesehl; Robert K. Prud’homme, Molecular Pharmaceutics, 2012
We present an in situ hydrophobic salt forming technique for the encapsulation of weakly hydrophobic, ionizable active pharmaceutical ingredients (API) into stable nanocarriers (NCs) formed via a rapid precipitation process. Traditionally, NC formation via rapid precipitation has been ...
How do formulation and process parameters impact blend and unit dose uniformity? Further analysis of the product quality research institute blend uniformity working group industry survey
21-12-2012 | Bruno C. Hancock, Salvador Garcia‐Munoz, Journal of Pharmaceutical Sciences, 2012
Abstract Responses from the second Product Quality Research Institute (PQRI) Blend Uniformity Working Group (BUWG) survey of industry have been reanalyzed to identify potential links between formulation and processing variables and the measured uniformity of blends and unit dosage forms. ...
A compatibility study of a secondary amine active pharmaceutical ingredient with starch: Identification of a novel degradant formed between desloratadine and a starch impurity using LC–MSn and NMR spectroscopy
14-12-2012 | Xin Yu, Alexei V. Buevich, Min Li, Xin Wang, Abu M. Rustum, Journal of Pharmaceutical Sciences, 2012
Abstract Active pharmaceutical ingredients (APIs) containing primary and secondary amine moieties have been extensively studied for their potential incompatibility with monosaccharides and disaccharides containing a reducing end such as glucose, lactose, and maltose because of the ...
Effect of substrates on naproxen‐polyvinylpyrrolidone solid dispersions formed via the drop printing technique
05-12-2012 | Hsin‐yun Hsu, Scott Toth, Garth J. Simpson, Lynne S. Taylor, Michael T. Harris, Journal of Pharmaceutical Sciences, 2012
Abstract Solid dispersions have been used to improve the bioavailability of poorly water‐soluble drugs. However, drug solid‐state phase, compositional uniformity, and scale‐up problems are issues that need to be addressed. To allow for highly controllable products, the drop printing (DP) ...
Investigation of the Capacity of Low Glass Transition Temperature Excipients to Minimize Amorphization of Sulfadimidine on Comilling
05-12-2012 | Vincent Curtin; Youness Amharar; Yun Hu; Andrea Erxleben; Patrick McArdle; Vincent Caron; Lidia Tajber; Owen I. Corr ..., Molecular Pharmaceutics, 2012
The coprocessing of active pharmaceutical ingredient (API) with an excipient which has a high glass transition temperature (Tg) is a recognized strategy to stabilize the amorphous form of a drug. This work investigates whether coprocessing a model API, sulfadimidine (SDM) with a series of low ...
Biowaiver monographs for immediate release solid oral dosage forms: Efavirenz
22-11-2012 | Rodrigo Cristofoletti, Anita Nair, Bertil Abrahamsson, D. W. Groot, Sabine Kopp, Peter Langguth, James E. Polli, Vin ..., Journal of Pharmaceutical Sciences, 2012
Abstract Literature data pertaining to the decision to allow a waiver of in vivo bioequivalence testing for the approval of immediate‐release (IR) solid oral dosage forms containing efavirenz as the only active pharmaceutical ingredient (API) are reviewed. Because of lack of conclusive ...
Netmeeting
